Interestingly, APP CTF accumulation has beenpostulated, together with inhibition of Notch processing [15], as a possible mechanism underlying cognitiveside effects in patients with AD treated with the γ-secretase inhibitor semagacestat [8, 37]. Here, APP is linked to Alzheimer disease.